Loading grant details…
Completed
SBIR-STTR RPGS
NIH (US)
Image-guided dosimetry-based alpha particle therapy for neuroblastoma.
$9.61M
USD
| Funder | NATIONAL CANCER INSTITUTE |
|---|---|
| Recipient Organization | Viewpoint Molecular Targeting, Inc. |
| Country | United States |
| Start Date | Aug 04, 2022 |
| End Date | Jul 31, 2025 |
| Duration | 1,092 days |
| Number of Grantees | 2 |
| Roles | Co-Investigator; Principal Investigator |
| Data Source | NIH (US) |
| Grant ID | 10677002 |
Grant Description
SIGNIFICANCE: Neuroblastoma is the most common pediatric cancer, accounting for 15% of cancer deaths, with a 5-yr survival of
All Grantees
Viewpoint Molecular Targeting, Inc.
Advertisement
Advertisement
Interested in applying for this grant?
Complete our application form to express your interest and we'll guide you through the process.
Apply for This GrantQuick Summary
Start Year
2022
End Year
2025
Grantees
2
Related Grants
AIDS Clinical Trials Group for Research on Therapeutics for...
NATIONAL INSTITUTE OF ALLERGY AND INFECT...
$762.2K USD
Leadership and Operations Center (LOC), AIDS Clinical Trials...
NATIONAL INSTITUTE OF ALLERGY AND INFECT...
$715K USD
Development of outpatient antiviral cocktails against SARS-C...
NATIONAL INSTITUTE OF ALLERGY AND INFECT...
$690.6K USD
Advertisement
